An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Clinical trial NCT00932451 · COMPLETED

Trial details

NCT number: NCT00932451
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2010-01-01
Primary completion: 2015-03-01
Enrollment: 1069

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.